Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $1,150,023.60 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Humacyte Price Performance

NASDAQ HUMA opened at $4.49 on Friday. Humacyte, Inc. has a 12 month low of $2.43 and a 12 month high of $9.97. The firm has a market capitalization of $565.11 million, a PE ratio of -3.27 and a beta of 1.47. The company’s 50 day simple moving average is $5.33 and its 200 day simple moving average is $6.17. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Humacyte in a research report on Wednesday, November 13th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $11.00.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently modified their holdings of HUMA. nVerses Capital LLC bought a new position in Humacyte during the second quarter valued at about $28,000. Concurrent Investment Advisors LLC acquired a new position in shares of Humacyte in the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. bought a new stake in shares of Humacyte in the 2nd quarter worth approximately $83,000. FORA Capital LLC acquired a new stake in Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new position in Humacyte in the second quarter worth approximately $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.